Preferred Label : Tizaterkib;
NCIt synonyms : ERK1/2 Inhibitor ATG-017;
NCIt definition : An orally bioavailable inhibitor of the extracellular signal-regulated kinases 1 (ERK1)
and 2 (ERK2), with potential antineoplastic activity. Upon oral administration, tizaterkib
specifically targets, binds to and inhibits the activity of the serine/threonine-protein
kinases ERK1 and ERK2, thereby preventing the phosphorylation of ERK1/2 substrates
and the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal
transduction pathways. This results in the inhibition of ERK-dependent proliferation
and survival of tumor cells. The MAPK/ERK pathway, also known as the RAS/RAF/MEK/ERK
pathway, is hyperactivated in a variety of tumor cell types due to mutations in upstream
targets. It plays a key role in the proliferation, differentiation and survival of
tumor cells.;
UNII : VO9KX45QIQ;
CAS number : 2097416-76-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2097416-76-5
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : AZD 0364; AZD-0364; ATG-017; ATG 017;
NCI Metathesaurus CUI : CL1642554;
Origin ID : C176765;
UMLS CUI : C5667213;
Semantic type(s)
- concept_is_in_subset
